JP2024501539A5 - - Google Patents

Info

Publication number
JP2024501539A5
JP2024501539A5 JP2023539973A JP2023539973A JP2024501539A5 JP 2024501539 A5 JP2024501539 A5 JP 2024501539A5 JP 2023539973 A JP2023539973 A JP 2023539973A JP 2023539973 A JP2023539973 A JP 2023539973A JP 2024501539 A5 JP2024501539 A5 JP 2024501539A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
cdr
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023539973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501539A (ja
JP7623497B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/062494 external-priority patent/WO2022144836A1/en
Publication of JP2024501539A publication Critical patent/JP2024501539A/ja
Publication of JP2024501539A5 publication Critical patent/JP2024501539A5/ja
Priority to JP2025005123A priority Critical patent/JP2025063183A/ja
Application granted granted Critical
Publication of JP7623497B2 publication Critical patent/JP7623497B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023539973A 2020-12-31 2021-12-30 NKp46およびCD123に結合する多機能性ナチュラルキラー(NK)細胞エンゲージャ Active JP7623497B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025005123A JP2025063183A (ja) 2020-12-31 2025-01-15 NKp46およびCD123に結合する多機能性ナチュラルキラー(NK)細胞エンゲージャ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20306717 2020-12-31
EP20306717.8 2020-12-31
US202163256950P 2021-10-18 2021-10-18
US63/256,950 2021-10-18
PCT/IB2021/062494 WO2022144836A1 (en) 2020-12-31 2021-12-30 Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025005123A Division JP2025063183A (ja) 2020-12-31 2025-01-15 NKp46およびCD123に結合する多機能性ナチュラルキラー(NK)細胞エンゲージャ

Publications (3)

Publication Number Publication Date
JP2024501539A JP2024501539A (ja) 2024-01-12
JP2024501539A5 true JP2024501539A5 (cg-RX-API-DMAC7.html) 2024-11-07
JP7623497B2 JP7623497B2 (ja) 2025-01-28

Family

ID=79316794

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023539973A Active JP7623497B2 (ja) 2020-12-31 2021-12-30 NKp46およびCD123に結合する多機能性ナチュラルキラー(NK)細胞エンゲージャ
JP2025005123A Pending JP2025063183A (ja) 2020-12-31 2025-01-15 NKp46およびCD123に結合する多機能性ナチュラルキラー(NK)細胞エンゲージャ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025005123A Pending JP2025063183A (ja) 2020-12-31 2025-01-15 NKp46およびCD123に結合する多機能性ナチュラルキラー(NK)細胞エンゲージャ

Country Status (11)

Country Link
US (2) US11692039B2 (cg-RX-API-DMAC7.html)
EP (1) EP4271709A1 (cg-RX-API-DMAC7.html)
JP (2) JP7623497B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250152662A (cg-RX-API-DMAC7.html)
AU (1) AU2021414400A1 (cg-RX-API-DMAC7.html)
CA (1) CA3206883A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023008958A2 (cg-RX-API-DMAC7.html)
IL (1) IL304124A (cg-RX-API-DMAC7.html)
MX (1) MX2023007901A (cg-RX-API-DMAC7.html)
TW (1) TWI905354B (cg-RX-API-DMAC7.html)
WO (1) WO2022144836A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6840682B2 (ja) * 2015-06-23 2021-03-10 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. 多重特異的抗原結合タンパク質
KR20250152662A (ko) * 2020-12-31 2025-10-23 사노피 NKp46 및 CD123에 결합하는 다기능성 자연살해(NK) 세포 관여자
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
KR102998144B1 (ko) * 2023-01-16 2026-07-31 주식회사 드노보 바이오테라퓨틱스 신규한 항-NKp46 항체 및 이의 용도
EP4438614A1 (en) * 2023-03-31 2024-10-02 Sanofi Methods for purifying heteromultimeric antibodies
WO2024224313A1 (en) * 2023-04-24 2024-10-31 Sanofi Use of cd123 nk cell engager for treating aml and related disorders
US20250064935A1 (en) * 2023-07-13 2025-02-27 Sanofi Natural killer cells and cd123 nk cell engager combination therapy
WO2025114919A1 (en) * 2023-11-28 2025-06-05 Sanofi Multifunctional natural killer (nk) cell engager combination therapy for treating hematological neoplastic disorders
WO2026055280A1 (en) * 2024-09-04 2026-03-12 Sanofi Interleukin 2 (il-2) and cd123 nk cell engager combination therapy

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US6177078B1 (en) 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
US7435549B1 (en) 1997-11-17 2008-10-14 Micromet Ag Method of identifying binding site domains that retain the capacity of binding to an epitope
JP2002541061A (ja) 1999-02-08 2002-12-03 メドベット・サイエンス・プロプライエタリー・リミテッド サイトカイン結合ドメイン
EP1161453A4 (en) 1999-02-08 2005-01-05 Medvet Science Pty Ltd CYTOKIN-BINDING DOMAIN
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
ATE510855T1 (de) 2000-03-06 2011-06-15 Univ Kentucky Res Found Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
NZ543202A (en) 2003-05-31 2008-04-30 Micromet Ag Pharmaceutical composition comprising a bispecific antibody for epcam
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
JP2011505386A (ja) 2007-12-06 2011-02-24 シーエスエル、リミテッド 白血病性幹細胞の阻害方法
PE20150680A1 (es) * 2008-11-26 2015-05-16 Amgen Inc Variantes de polipeptidos receptores de activina iib y aplicaciones de estos
US20100209341A1 (en) 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
ES2550639T3 (es) 2009-04-27 2015-11-11 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-IL-3Ralfa para su utilización en el tratamiento de un tumor de la sangre
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
AU2011217728B2 (en) 2010-02-17 2013-03-14 Csl Limited Compositions and methods for targeting type 1 interferon producing cells
BR112012031189B1 (pt) 2010-06-07 2021-10-26 Stepan Company Composição, composição biocida diluível e método de limpeza de uma superfície dura
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
US20130210860A1 (en) 2010-10-06 2013-08-15 Kowa Co., Ltd. Prophylactic and/or therapeutic agent against lymphedema
WO2012059857A2 (en) 2010-11-01 2012-05-10 Symphogen A/S Pan-her antibody composition
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
US9598499B2 (en) 2010-12-30 2017-03-21 Institut National De La Santé Et De La Recherche Médicale (Inserm) Antigen binding formats for use in therapeutic treatments or diagnostic assays
WO2012106615A1 (en) * 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
GB201203051D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
US20160046718A1 (en) 2013-03-14 2016-02-18 Csl Limited Agents that neutralize il-3 signalling and uses thereof
WO2014138805A1 (en) 2013-03-14 2014-09-18 Csl Limited Anti il-3r alpha agents and uses thereof
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
TR201910814T4 (tr) 2014-03-19 2019-08-21 Cellectis Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri.
US11041021B2 (en) * 2014-05-23 2021-06-22 University Of Florida Research Foundation, Incorporated Car based immunotherapy
LT3148579T (lt) 2014-05-28 2021-05-25 Agenus Inc. Anti-gitr antikūnai ir jų panaudojimo būdai
EP3158064A1 (en) 2014-06-17 2017-04-26 Cellectis Cd123 specific multi-chain chimeric antigen receptor
AU2015279321B2 (en) 2014-06-27 2021-03-04 Innate Pharma, S.A. Multispecific antigen binding proteins
JP6822849B2 (ja) 2014-06-27 2021-01-27 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. 多重特異的NKp46結合タンパク質
CN105367657B (zh) 2014-08-14 2019-09-13 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
ES2688035T3 (es) 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
DK3189081T3 (da) 2014-09-05 2020-05-04 Janssen Pharmaceutica Nv Cd123-bindende midler og anvendelser deraf
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
AR103488A1 (es) 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
EP3250602A1 (en) 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
TWI787796B (zh) 2015-05-04 2022-12-21 美商Cytomx生物製藥公司 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
TW201709932A (zh) 2015-06-12 2017-03-16 西雅圖遺傳學公司 Cd123抗體及其共軛物
CA2990398A1 (en) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-cd123-antibodies
JP6840682B2 (ja) 2015-06-23 2021-03-10 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. 多重特異的抗原結合タンパク質
AU2016284871B2 (en) 2015-06-23 2022-09-29 Innate Pharma Multispecific NK engager proteins
CA2994746A1 (en) 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2017096276A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
AU2016364895A1 (en) 2015-12-02 2018-06-07 Agenus Inc. Anti-GITR antibodies and methods of use thereof
MA43389A (fr) 2015-12-02 2021-05-12 Agenus Inc Anticorps anti-ox40 et leurs procédés d'utilisation
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
CA3007898A1 (en) 2015-12-28 2017-07-06 Innate Pharma Variable regions for nkp46 binding proteins
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白
EP3713959A1 (en) 2017-11-21 2020-09-30 Innate Pharma Multispecific antigen binding proteins
KR20210133261A (ko) 2019-02-26 2021-11-05 소렌토 쎄라퓨틱스, 인코포레이티드 Bcma에 결합하는 항원 결합 단백질
KR20250152662A (ko) * 2020-12-31 2025-10-23 사노피 NKp46 및 CD123에 결합하는 다기능성 자연살해(NK) 세포 관여자
CN117321087A (zh) 2021-03-26 2023-12-29 先天制药公司 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
CN117616050A (zh) 2021-06-09 2024-02-27 先天制药公司 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质

Similar Documents

Publication Publication Date Title
JP2019122405A5 (cg-RX-API-DMAC7.html)
JP2025063183A5 (cg-RX-API-DMAC7.html)
AU2017298535B2 (en) Bispecific proteins and methods for preparing same
JP2024508671A5 (cg-RX-API-DMAC7.html)
JP2023538945A5 (cg-RX-API-DMAC7.html)
JP2023134618A5 (cg-RX-API-DMAC7.html)
JP2024056687A5 (cg-RX-API-DMAC7.html)
JP2020508655A5 (cg-RX-API-DMAC7.html)
JP2021520832A5 (cg-RX-API-DMAC7.html)
RU2010133892A (ru) Гуманизированные моноклональные антитела против человеческого nkg2a
JP2021515793A5 (cg-RX-API-DMAC7.html)
RU2012147286A (ru) Гуманизированные антитела к фактору d и их применения
JP2023511376A5 (cg-RX-API-DMAC7.html)
JP2024537779A5 (cg-RX-API-DMAC7.html)
JP2021511387A5 (cg-RX-API-DMAC7.html)
JP2023139025A (ja) 二重特異性抗原結合コンストラクト
JP2025508317A5 (cg-RX-API-DMAC7.html)
JP2023531230A5 (cg-RX-API-DMAC7.html)
JP2023551981A5 (cg-RX-API-DMAC7.html)
JP2023518408A5 (cg-RX-API-DMAC7.html)
IL296427B1 (en) Isoform-selective anti-TGF-β antibodies and methods of use
CA2538725A1 (en) Nogo-a binding molecules and pharmaceutical use thereof
JP2024515301A5 (cg-RX-API-DMAC7.html)
JP2022514148A5 (cg-RX-API-DMAC7.html)
JP2021531757A5 (cg-RX-API-DMAC7.html)